Misplaced Pages

Beclometasone/formoterol

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Inhalable drug

Pharmaceutical compound
Beclometasone/formoterol
Combination of
Beclometasone dipropionateGlucocorticoid
Formoterol fumarateLong-acting β2 agonist
Clinical data
Trade namesFostair
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Inhalation
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)

Beclometasone/formoterol, sold under the brand name Fostair, is an inhalable fixed-dose combination drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It contains beclometasone dipropionate and formoterol fumarate dihydrate. It is inhaled.

It was approved for medical use in the United Kingdom in 2007, and in Australia in February 2020. It is on the World Health Organization's List of Essential Medicines.

References

  1. ^ "Fostair 100/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 3 March 2020. Retrieved 18 July 2020.
  2. "Fostair 200/6 micrograms per actuation pressurised inhalation solution - Summary of Product Characteristics (SmPC)". (emc). 13 February 2019. Retrieved 18 July 2020.
  3. "Fostair NEXThaler 200 micrograms/6 micrograms per actuation inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 16 April 2019. Retrieved 18 July 2020.
  4. "Australian Product Information - Fostair 100/6 (Beclometasone dipropionate and formoterol (eformoterol) fumarate dihydrate) pressurised inhalation solution". Therapeutic Goods Administration (TGA). April 2020. Retrieved 22 September 2020.
  5. "AusPAR: Beclometasone dipropionate/formoterol (eformoterol) fumarate dihydrate". Therapeutic Goods Administration (TGA). 3 August 2020. Retrieved 22 September 2020.
  6. World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

Further reading

  • Foster K, Wong CY (July 2024). "Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: a comprehensive review of Fostair and Trimbow". Journal of Pharmacy and Pharmacology. doi:10.1093/jpp/rgae090. PMID 38954755.
Drugs for obstructive airway diseases: asthma/COPD (R03)
Adrenergics, inhalants
Short-acting β2 agonists
Long-acting β2 agonists
Ultra-long-acting β2 agonists
Other
Glucocorticoids
Anticholinergics/
muscarinic antagonist
Mast cell stabilizers
Xanthines
Eicosanoid inhibition
Leukotriene antagonists
Arachidonate 5-lipoxygenase inhibitors
Thromboxane receptor antagonists
Non-xanthine PDE4 inhibitors
Others/unknown
Combination products
Glucocorticoids and antiglucocorticoids (D07, H02)
Glucocorticoids
Natural
Synthetic
Antiglucocorticoids
Synthesis modifiers
See also
Glucocorticoid receptor modulators
Mineralocorticoids and antimineralocorticoids
List of corticosteroids
Portal:


Stub icon

This drug article relating to the respiratory system is a stub. You can help Misplaced Pages by expanding it.

Categories: